Design and rationale of a randomized trial comparing the Blalock-Taussig and right ventricle-pulmonary artery shunts in the Norwood procedure.

Richard G. Ohye
J William Gaynor
Nancy S. Ghanayem
Caren S. Goldberg
Peter C. Laussen

See next page for additional authors

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/papers

Part of the Cardiology Commons, Cardiovascular System Commons, Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons, Pediatrics Commons, Surgery Commons, and the Surgical Procedures, Operative Commons

Recommended Citation

This Article is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for inclusion in Manuscripts, Articles, Book Chapters and Other Papers by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact library@cmh.edu.
Design and rationale of a randomized trial comparing the Blalock–Taussig and right ventricle–pulmonary artery shunts in the Norwood procedure

Richard G. Ohye, MD, a J. William Gaynor, MD, b Nancy S. Ghanayem, MD, c Caren S. Goldberg, MD, MS, a Peter C. Laussen, MBBS, d Peter C. Frommelt, MD, c Jane W. Newburger, MD, MPH, d Gail D. Pearson, MD, ScD, e Sarah Tabbutt, MD, PhD, a Gil Wernovsky, MD, b Lisa M. Wruck, PhD, a Andrew M. Atz, MD, f Steve D. Colan, MD, d James Jaggers, MD, h Brian W. McCrindle, MD, MPH, i Ashwin Prakash, MD, j Michael D. Puchalski, MD, k Sarah Tabbutt, ScD, l Mario P. Stylianou, PhD, a and Lynn Mahony, MD, f for the Pediatric Heart Network Investigators (see Appendix)

Objective: The initial palliative procedure for patients born with hypoplastic left heart syndrome and related single right ventricle anomalies, the Norwood procedure, remains among the highest risk procedures in congenital heart surgery. The classic Norwood procedure provides pulmonary blood flow with a modified Blalock–Taussig shunt. Improved outcomes have been reported in a few small, nonrandomized studies of a modification of the Norwood procedure that uses a right ventricle–pulmonary artery shunt to provide pulmonary blood flow. Other nonrandomized studies have shown no differences between the two techniques.

Methods: The Pediatric Heart Network designed a randomized clinical trial to compare outcomes for subjects undergoing a Norwood procedure with either the right ventricle–pulmonary artery or modified Blalock–Taussig shunt. Infants with a diagnosis of single, morphologically right ventricle anomaly who are undergoing a Norwood procedure are eligible for inclusion in this study. The primary outcome is death or cardiac transplant 12 months after random assignment. Secondary outcomes include postoperative morbidity after Norwood and stage II palliation procedures, right ventricular function and pulmonary arterial growth at stage II palliation, and neurodevelopmental outcomes at 14 months old. Incidence of adverse events will also be compared between treatment groups.

Conclusion: This study will make an important contribution to the care of patients with hypoplastic left heart syndrome and related forms of single, morphologically right ventricle. It also establishes a model with which other operative interventions for patients with congenital cardiovascular malformations can be evaluated in the future.
aneurysms; (2) free pulmonary insufficiency, resulting in ventricular dilation, (3) decreased PA growth related to the lack of forward flow during diastole, and (4) need for earlier stage II procedure because of hypoxemia.\textsuperscript{1,5,8-10}

No prospective randomized trial has compared patient outcomes after a Norwood procedure with the MBTS with those after one incorporating the RV-PA shunt. Several case series that used historical series of patients with MBTS as a control group reported improved short-term survival with the RV-PA shunt\textsuperscript{2,4,11,12} In contrast, a retrospective review comparing contemporaneous results of stage I reconstruction with the MBTS versus the RV-PA shunt performed during the same time period showed no differences in mortality or short-term outcomes.\textsuperscript{13} A second study also showed no difference in early morbidity and mortality between the two shunts, although the patients who underwent the RV-PA shunt were discharged from the hospital earlier than were those who underwent the MBTS.\textsuperscript{9} That same cohort was later reported to have no difference in mortality or morbidity after stage II palliation between MBTS and RV-PA shunt groups.\textsuperscript{5} All these studies are confounded by the fact that the type of shunt placed was determined by surgeon preference. In addition, the anatomic subtypes differed significantly between cohorts. Thus there is a need for a rigorous, randomized clinical trial to determine the optimal strategy. The purpose of this report is to describe the design and rationale of a multisite, randomized clinical trial to compare outcomes associated with the RV-PA shunt with those of the MBTS in a prospective and randomized fashion.

**Materials and Methods**

**Study Overview**

This trial will test the hypothesis that the RV-PA shunt is associated with a decrease relative to the MBTS in the frequency of the combined end point of mortality or transplant at 12 months after random assignment. We plan to enroll 466 infants to be randomly assigned to undergo either MBTS or RV-PA shunt. The concept for this study was developed by investigators at the University of Michigan Medical School, the Children’s Hospital of Philadelphia, Children’s Hospital of Wisconsin, and Children’s Hospital Boston, who collaborated with the National Heart, Lung, and Blood Institute–funded Pediatric Heart Network (PHN)\textsuperscript{14} to develop the final study design. The study is being conducted at 14 clinical centers. A flow chart of the study design is shown in Figure 1. An independent Data and Safety Monitoring Board and an independent medical monitor have been established by the National Heart, Lung, and Blood Institute to monitor this trial for data quality and safety.

**Subject Selection**

Subject selection criteria were defined to ensure a relatively homogeneous group of subjects with a functionally single ventricle lesion characterized by a single morphologically RV. Inclusion and exclusion criteria are shown in Table 1.

**Randomization and Stratification**

Subjects are assigned to treatment group with randomly permuted blocks within strata defined by the presence or absence of aortic atresia and the presence or absence of obstructed pulmonary venous return.\textsuperscript{15-18} Obstructed pulmonary venous return is defined by the use of postnatal intervention, including balloon septostomy, open atrial septectomy, or urgent Norwood procedure. Aortic atresia is defined by 2-dimensional and color Doppler echocardiographic findings interpreted at the local center. Because of potential differences in surgeon experience and operative techniques, dynamic balancing by surgeon ensures that treatment arm totals are balanced within each.
Technical Considerations of Surgery

Each center will strive to maintain a consistent approach to peroperative care and the conduct of the operation, regardless of the shunt group to which the subject is randomly assigned, for the duration of the trial. These variables include such techniques as cardiopulmonary bypass (CPB, including the use of regional cerebral perfusion, hematocrit levels, and methods of pH monitoring) and management in the intensive care unit before and after surgery. Despite these efforts to standardize the care for the duration of the trial, however, management techniques invariably change with time. To minimize the impact of these changes, permuted block randomization will be used, as mentioned previously. In addition, extensive data on peroperative management will be recorded to allow analysis of significant changes in management during the trial time frame.

The MBTS and RV-PA shunts are constructed of unvalved polytetrafluoroethylene tube grafts with standard surgical techniques.2,16 Features of cardiac anatomy recognized in the operating room after random assignment occasionally render the performance of the MBTS or RV-PA shunt technically impossible. Although every effort is made to use the shunt to which the subject has been randomly assigned, the surgeon may choose an alternative shunt at any time during the operation if it is deemed to be in the subject’s best interest because of unanticipated anatomic constraints. If the innominate artery is not appropriate for the MBTS, such as in the scenario of an aberrant right subclavian artery and inadequate caliber right carotid artery, the subject will be considered for an aortopulmonary shunt. Because a shunt arising from the aorta is a shunt from a systemic artery to the PA, its use will not be considered a treatment crossover. On rare occasions, if the surgeon considers that the MBTS or another shunt from a systemic artery to the PA cannot be performed, a crossover will occur. Another possibility is the finding of a large conal branch on the RV free wall in the area of the proposed origin of the RV-PA shunt. In this case, the subject will also cross over to the alternative shunt. It is also possible that after the placement of the initial randomly assigned shunt, the subject may not be able to be separated successfully from CPB. The surgeon may place another type of shunt in an attempt to save the subject’s life.

Study Measurements and Subject Follow-up

Baseline data. Demographic and preoperative data include pregnancy history, fetal diagnosis, birth weight, race, gender, gestational age, Apgar scores, clinical status and anatomic diagnosis at presentation, occurrence of important preoperative complications, age at operation, and genetic evaluation findings (if performed). All centers perform 2-dimensional echocardiographic studies, which are reviewed both locally and in the 2-dimensional echocardiography core laboratory to evaluate anatomy and ventricular function. Centers with 3-dimensional echocardiography capability also collect these studies for local interpretation and review by the 3-dimensional echocardiography core laboratory. Any additional interventions and important events, as defined by the protocol, are recorded.

Follow-up visits. The schedule of data collection is summarized in Table 2. Follow-up data are obtained at five times: (1) during hospitalization for the Norwood procedure, (2) before the stage II palliation, (3) during hospitalization for the stage II palliation, (4) 12 months after random assignment, and (5) at age 14 months. Specific data and studies include the following:

- Echocardiographic and Doppler images obtained for analysis after the Norwood procedure, before the stage II palliation and at age 14 months;
- Height, weight, and head circumference measured at the time of each echocardiogram;
- Apolipoprotein E genotype (APOE) obtained by buccal swab from subjects with consent during the hospitalization for the Norwood procedure (consent for genotyping not required for participation in the main trial);
- Cardiac catheterization data and images, if a routine cardiac catheterization is performed for clinical indications before the stage II palliation;
- Vital status and whether a heart transplant has been performed (collected 12 months after random assignment only);
- The Bayley Scales of Infant Development–II (Harcourt Assessment, Inc, San Antonio, Tex), MacArthur-Bates Communicative Development Inventories (Singular Publishing Group, San Diego, Calif), Hollingshead Four Factor Scale (Four-factor index of social status [unpublished manuscript]; Yale University, New Haven, Conn), and Functional Status II–Revised questionnaire (Albert Einstein College of Medicine, Bronx, NY) at 14 months old.

Echocardiographic data, APOE genotype, and cardiac catheterization data are centrally interpreted in PHN core laboratories. To cover long-term follow-up of this unique patient population, the consent form includes permission to contact each family annually until the subject reaches the age of 5 years.

TABLE 1. Inclusion and exclusion criteria

<table>
<thead>
<tr>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Diagnosis of hypoplastic left heart syndrome or related single, morphologically right ventricle anomaly</td>
<td>- Single, morphologically left ventricle anomaly</td>
</tr>
<tr>
<td>- Planned Norwood procedure</td>
<td>- Preoperative identification of anatomic features rendering either modified Blalock–Taussig shunt or right ventricle–pulmonary artery shunt technically impossible</td>
</tr>
<tr>
<td>- Informed consent of parent or legal guardian</td>
<td>- Any major congenital abnormality (eg, congenital diaphragmatic hernia, tracheoesophageal fistula) or acquired extracardiac disorder (eg, meconium aspiration with need for high-frequency ventilation, persistent renal failure requiring dialysis) that investigator considered could independently affect likelihood of subject meeting primary end point</td>
</tr>
</tbody>
</table>

The Bayley Scales of Infant Development–II (Harcourt Assessment, Inc, San Antonio, Tex), MacArthur-Bates Communicative Development Inventories (Singular Publishing Group, San Diego, Calif), Hollingshead Four Factor Scale (Four-factor index of social status [unpublished manuscript]; Yale University, New Haven, Conn), and Functional Status II–Revised questionnaire (Albert Einstein College of Medicine, Bronx, NY) at 14 months old.
Trial Outcomes
The primary outcome is death or cardiac transplant by 12 months after randomization. Secondary outcomes are listed in Table 3.

Blinding of Treatment Group Assignment
This trial is not blinded with respect to knowledge of treatment assignment. Blinding is not feasible for most of the personnel caring for the subjects, because the treatment strategies produce differences in physical examination findings and in the follow-up studies performed for the secondary end points, such as echocardiography and cardiac catheterization. Only the specialists who perform the neurodevelopmental testing and the APOE genotyping are blinded to treatment assignment.

Statistical Considerations
For the primary trial result, the proportion of subjects with MBTS versus RV-PA shunt reaching the primary trial end point by 12 months after randomization will be compared with a Fisher exact test. Furthermore, to test the hypothesis that differences in the surgical strategies are present early, a comparison of the primary end point in the two trial arms will be conducted with the Kaplan–Meier method for estimation and the Gehan–Wilcoxon test, which places more weight on early failure times because of weights determined by risk set sample size. A competing risks analysis (death vs stage II surgery performed vs no progression through additional stages) will also be conducted to characterize subject risk more fully by treatment group.

All primary analyses will be performed on an intention-to-treat basis. This approach implies that the rare randomly allocated subject who receives neither trial shunt (eg, in the event of death between assignment and the Norwood procedure) would remain classified in the assigned surgical group for analysis. If it is clear that the decision not to proceed with the Norwood procedure has not been influenced by knowledge of the assigned shunt, however, then no bias is incurred, intention-to-treat is preserved, and those subjects will be excluded from analysis. A review panel will evaluate each case in which a randomly allocated subject receives neither trial shunt. If the review panel determines that the decision to use neither trial shunt was clearly not influenced by treatment assignment (eg, subject dies before surgery), then that subject will be excluded from all analyses. Primary outcome data will be collected for these subjects so that the impact of the exclusions on primary analysis results can be assessed.

Secondary analyses will compare treatment groups as follows: (1) with covariate-adjusted analysis, (2) according to which shunt was actually in place at the conclusion of the operative procedure, and (3) after exclusion of any randomly assigned subjects subsequently found to have been ineligible for the trial at the time of enrollment.

Treatment assignment by prespecified subgroup interaction analyses are planned to estimate the effects of birth weight, preoperative tricuspid regurgitation, type of cerebral perfusion during stage I palliation, experience of the surgeon, and center volume (Table 4).

To monitor the trial for large treatment differences, three formal interim analyses are planned, timed to occur when one quarter, one half, and three quarters of subjects would be expected to reach the 12-month visit. An O’Brien–Fleming stopping boundary with a Lan–DeMets adjustment will be used for this purpose. Adverse event rates by trial arm, as well as death and transplantation rates in aggregate, are reported to the Data and Safety Monitoring Board twice a year. To preserve the type I error rate for primary analysis, death and transplantation rates by treatment arm are reported during prespecified interim analyses only.

This trial is powered to detect differences in the primary composite end point (death or cardiac transplant) by 12 months after random assignment. A review of previous data from the participating centers for infants born in 2002 and 2003 was performed to calculate an estimate of the incidence of death or cardiac transplant for each shunt under consideration. For subjects undergoing a Norwood procedure with MBTS at least 1 year earlier, the incidence of death or transplant by 12 months after surgery was 28% (65/236). The expected mortality for the RV-PA shunt was based on the three member centers routinely performing the RV-PA shunt exclusively or in a significant proportion of their Norwood procedures. The data on Norwood procedures with RV-PA shunts were sparse, and not all patients had reached 1 year old. Because previously reported data indicate that events after the stage II procedure are rare, all deaths and cardiac transplants, regardless of whether the patient had reached 1 year of age, were counted. For subjects receiving a RV-PA shunt at the three
centers of interest, the 12-month mortality or transplant rate was assumed to be 16% (14/87). The trial was thus designed to detect a 12% difference with 85% power at a 2-sided significance level of .05. After 2% inflation to account for three interim analyses, this required a total of 466 subjects.

**Trial Organization**
The PHN Single Ventricle Reconstruction Study Committee and PHN Steering Committee, together with the National Heart, Lung, and Blood Institute, are responsible for all aspects of this study. The protocol has been approved by an independent Protocol Review Committee and Data and Safety Monitoring Board, and by the institutional review boards at each clinical center and at the Data Coordinating Center. All centers follow the same protocol and study procedures.

**Comment**

Rationale for Outcome Measures
Infants born with HLHS and related conditions have relatively high mortality, unlike neonates with other forms of congenital heart disease. The most fundamental research question to answer in a surgical trial in this population, therefore, is whether the child survives to at least 1 year old, and whether the heart requires replacement before then. The primary outcome, death or cardiac transplant by 12 months after random assignment, reflects this clinical imperative. In addition, this definitive end point should facilitate clear interpretation of the trial results by the medical teams taking care of these patients.

The surgical strategy could affect the postoperative course after the stage I procedure, as well as perioperative morbidity

**TABLE 3. Secondary outcome variables**

<table>
<thead>
<tr>
<th>Morbidity after the Norwood procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Open sternum (yes or no)</td>
</tr>
<tr>
<td>2. Extracorporeal membrane oxygenation (yes or no)</td>
</tr>
<tr>
<td>3. Cardiopulmonary resuscitation (yes or no)</td>
</tr>
<tr>
<td>4. Time to initial extubation (h)</td>
</tr>
<tr>
<td>5. Duration of ventilation (total d)</td>
</tr>
<tr>
<td>6. Length of intensive care unit stay (d)</td>
</tr>
<tr>
<td>7. Length of hospital stay from day of surgery (d)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Incidence of unintended cardiovascular interventional procedures (composite and individual)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Balloon dilation of shunt or branch pulmonary arteries</td>
</tr>
<tr>
<td>2. Stent placement in shunt or branch pulmonary arteries</td>
</tr>
<tr>
<td>3. Shunt revision</td>
</tr>
<tr>
<td>4. Crossover between MBTS and RV-PA shunt</td>
</tr>
<tr>
<td>5. Balloon dilation, stent placement, or surgical revision of neoaorta</td>
</tr>
<tr>
<td>6. PA reconstructions other than those undertaken as standard component of stage II procedure</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Evaluation of RV function by 2-dimensional echocardiography</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Right ventricular BSA-adjusted Z scores for diastolic and systolic volumes and age-adjusted Z scores for ejection fraction</td>
</tr>
<tr>
<td>2. Absolute values for diastolic and systolic volumes and ejection fraction</td>
</tr>
<tr>
<td>3. (dP/dt) obtained from the tricuspid regurgitation jet</td>
</tr>
<tr>
<td>4. Severity of tricuspid regurgitation</td>
</tr>
<tr>
<td>5. Doppler tissue imaging of RV</td>
</tr>
<tr>
<td>a. Systolic annular acceleration and peak velocity</td>
</tr>
<tr>
<td>b. Isovolumic myocardial acceleration</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pulmonary arterial growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Angiographic PA cross-sectional area, as determined by the Nakata index</td>
</tr>
<tr>
<td>2. Ratio of distal to proximal PA diameter, measured by angiography</td>
</tr>
<tr>
<td>3. Incidence of angiographically discrete PA stenosis</td>
</tr>
<tr>
<td>4. Change in echocardiographic Nakata index from Norwood procedure to stage II procedure</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stage II perioperative morbidity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Cardiopulmonary resuscitation (yes or no)</td>
</tr>
<tr>
<td>2. Time to initial extubation (hours)</td>
</tr>
<tr>
<td>3. Duration of ventilation (total d)</td>
</tr>
<tr>
<td>4. Length of intensive care unit stay (d)</td>
</tr>
<tr>
<td>5. Length of hospital stay from day of stage II surgery (d)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Neurodevelopmental outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Bayley Scales of Infant Development II</td>
</tr>
<tr>
<td>2. MacArthur Communicative Developmental Index</td>
</tr>
<tr>
<td>3. Functional Status II–Revised questionnaire</td>
</tr>
</tbody>
</table>

MBTS, Modified Blalock-Taussig shunt; RV, right ventricle; PA, pulmonary artery, BSA, body surface area, \(dP/dt\), estimated maximum first derivative of ventricular pressure.
The MBTS and RV-PA shunt strategies differ most significantly in their approach to providing pulmonary arterial blood flow, which may influence subsequent PA size, rate of growth, and stenosis. These variables are of clinical significance in their own right, but they also can affect subsequent outcome, because small PA size is a known risk factor for patients undergoing both the stage II palliation and the Fontan procedure.  

The impact of the MBTS relative to the RV-PA shunt on PA growth and stenosis will be evaluated.  

Multiple studies have demonstrated that preschool and school-aged children with HLHS have neurocognitive and behavioral abnormalities. Risk factors for such abnormalities include underlying congenital structural central nervous system abnormalities, genetic syndromes, disturbed fetal cerebral hemodynamics, preoperative seizures, intraoperative events related to CPB, and such postoperative factors as low cardiac output syndrome, seizures, and longer of hospital stay.

It is hypothesized that relative to the MBTS the RV-PA shunt may reduce neurodevelopmental impairment through improved postoperative oxygen delivery, less steal from the systemic circulation through the shunt into the lungs, and higher diastolic blood pressure. Measures of neurodevelopmental status will profile the motor and cognitive capabilities of study subjects. The effects of known modifiers of neurodevelopment will be evaluated in the analysis. One such modifier is the APOE*E2 allele, recently found to be associated with worse neurologic outcome in patients undergoing CPB. APOE genotype will be assessed as a component of neurodevelopmental outcome.

Limitations

Blinding of subjects and caregivers is desirable in clinical trials because of the potential for bias in medical care and in adjudication of treatment outcomes. Practical considerations preclude blinding in most surgical trials, however, including this one. In the absence of blinding, it is important to ensure that random assignment is conducted properly and that end points are assessed objectively. The PHN’s standard quality assurance process will be used for close monitoring of screening and randomization. Although the primary end point is a composite, most of the events are expected to be deaths, an objective measure. If a significant number of cardiac transplants occur, the transplant criteria will be adjudicated independently in each case.

This trial, like many other studies of rare conditions, is powered to detect a relatively large difference in the primary end point (16% vs 28%), so a smaller but clinically important difference might not be detected. Powering the study to detect a smaller difference, however, would require many more subjects and thus possibly a longer study duration. The decision to adopt the current design was made to avoid the loss of equipoise and potential confounding changes in

**TABLE 4. Subgroup factors for estimation of differential treatment effect**

- Birth weight <2500 g vs ≥2500 g
- Preoperative tricuspid regurgitation proximal jet width ≤2.5 mm vs >2.5 mm determined by echocardiography
- Cerebral perfusion during stage I palliation as deep hypothermic circulatory arrest vs regional cerebral perfusion (if subject received both types of cerebral perfusion during surgery, classification was deep hypothermic circulatory arrest)
- Experience of the surgeon as average number of Norwood procedures performed on randomized subjects per year (as a continuous variable) and classified as ≤5, 5-10, 11-15, or >15 procedures/y
- Center volume as average number of Norwood procedures performed on randomized subjects per year (as continuous variable) and classified as ≤10, 11-25, 26-40, or >40 procedures/y
surgical techniques and perioperative care that could occur over a longer time.

To maximize enrollment, the number of secondary outcome measures is intentionally limited to minimize the number of extra measurements and thus the burden on subjects and families. For example, although 48-hour electroencephalographic monitoring or head magnetic resonance imaging might provide mechanistic data to explain abnormalities in neurodevelopment, these studies are not included. In addition, the trial may be underpowered for some of the secondary end point analyses.

Importance of Knowledge to Be Gained

Techniques for management of congenital heart lesions have been adopted solely on the basis of expert consensus and retrospective analysis, rather than on data from prospective, randomized clinical trials. The primary goal of the PHN is to promote evidence-based clinical care for children and adults with congenital heart disease. This trial offers a unique opportunity for systematic comparison of two surgical procedures for which equipoise exists among surgeons and for determination of the time course of risk and benefit for each procedure. Not only will the main results provide an unbiased estimate of relative efficacies of the two shunts, but standardized information characterizing the clinical course in a large unselected cohort of infants with HLHS will be obtained for the first time. The results of this study will make an important contribution to the management of the highest-risk group of patients with congenital heart disease. Another important contribution of this trial will be establishment of the basis for long-term follow-up of a well-characterized cohort of patients with little systematic information currently available. Finally, this trial provides a feasible model of collaborative research for the evaluation of other operative interventions in patients with congenital cardiovascular malformations.

References


Appendix: Pediatric Heart Network Investigators

**National Heart, Lung, and Blood Institute.** Gail Pearson (Project Director), Victoria Pemberton (Deputy Project Director), Rae-Ellen Kavey, Judith Massicot-Fisher, Marsha Mathis, Mario Stylianou

**Network Chair.** University of Texas Southwestern Medical Center, Lynn Mahony

**Data Coordinating Center.** New England Research Institutes, Lynn Sleeper (PI), Steven D. Colan, Patty Connell, Victoria Murtov, Lisa Wruck, Lisa Virzi, David F. Teitel

**Core clinical site investigators.** Children’s Hospital Boston, Jane Newburger (PI), Peter Laussen, Pedro del Nido, Roger Breithart, Jami Levine, Ellen McGrath, Carolyn Dunbar-Masterson; Children’s Hospital of New York, Daphne Hsu (PI), Ashwin Prakash, Ralph Mosca, Darlene Servedio; Children’s Hospital of Philadelphia, Victoria L. Vetter (PI), Sarah Tabbutt, J. William Gaynor (Study Co-Chair), Marisa Nolan, Stephanie Piacentino; Cincinnati Children’s Medical Center, D. Woodrow Benson (PI), Catherine Dent, Lois Bogen-schutz, Teresa Barnard; Duke University, Page A. W. Anderson (PI), Piers Barker, James Jaggers, Charlie Sang, Jr, Wesley Covitz, Theodore Koutlas, Ming Xu, Lori Jo Sutton, Kari Crawford; Medical University of South Carolina, J. Philip Saul (PI), Andrew Atz, Scott Bradley, Eric Graham, Girish Shirali, Teresa Atz; Primary Children’s Medical Center, Salt Lake City, Utah, LuAnn Minich (PI), Michael Pulchalski, John Hawkins, Ruth Metas, Marian Sharrow; Hospital for Sick Children, Toronto, Brian McCrindle (PI) Joel Kirsh, Chris Caldarone, Elizabeth Radoweiski, Susan McIntyre; University of Michigan, Richard G. Ohye (Study Chair), Caren S. Goldberg, Cheryl Nowak; Children’s Hospital of Wisconsin, Nancy Ghanayem, James Tweddell, Kathy Mus-satto, Michele Frommelt, Lisa Young-Borkowski

**Auxiliary sites.** Children’s Hospital Los Angeles, Alan Lewis, Vaughn Starnes, Nancy Pike; Congenital Heart Institute of Florida, Jeff Jacobs, James, Hulta, Tina Merola; Emory University, Kirk Kanter, William Mahle, Joel Bond; Nemours Cardiac Center, Christian Pizarro, Carol Prospero; University of Texas Southwestern Medical Center, Tia Tortoriello, Deborah McElroy, Deborah Town.

**Angiography core laboratory.** Duke University, John Rhodes

**Echocardiography core laboratories.** Children’s Hospital of Wisconsin, Peter Frommelt; Children’s Hospital Boston, Gerald Marx.

**Genetics core laboratory.** Children’s Hospital Philadelphia, Catherine Stolle

**Protocol Review Committee.** Michael Artman (Committee Chair), Erle Austin, Timothy Feltes, Julie Johnson, Thomas Kitzner, Jeffrey Krischer, G. Paul Matherne

**Data and Safety Monitoring Board.** John Kugler (Board Chair), David J. Driscoll, Mark Galantowicz, Sally A. Hunsberger, Thomas J. Knight, Holly Taylor, Catherine L. Webb